NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Odonate Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $37.10 -0.15 (-0.40 %) (As of 08/7/2020 11:38 AM ET) Add Compare Share Today's Range$36.82Now: $37.10▼$37.2350-Day Range$35.40MA: $39.12▼$42.7452-Week Range$18.07Now: $37.10▼$46.50Volume298 shsAverage Volume89,823 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/ABeta1.02 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.5 Analyst's Opinion Consensus RatingOdonate Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Odonate Therapeutics has a potential downside of 30.0% from its current price of $37.16.Amount of Analyst CoverageOdonate Therapeutics has received no research coverage in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesOdonate Therapeutics has received 150 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOdonate Therapeutics has received 201 “underperform” votes. (Add your “underperform” vote.)Community SentimentOdonate Therapeutics has received 57.26% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote “Outperform” if you believe ODT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOdonate Therapeutics does not currently pay a dividend.Dividend GrowthOdonate Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Odonate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders48.90% of the stock of Odonate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.78% of the stock of Odonate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Odonate Therapeutics are expected to decrease in the coming year, from ($4.30) to ($4.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Odonate Therapeutics is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Odonate Therapeutics is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOdonate Therapeutics has a P/B Ratio of 11.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ODT Previous Symbol CUSIPN/A CIK1717452 Webwww.odonate.com Phone858-731-8180Debt Debt-to-Equity RatioN/A Current Ratio5.00 Quick Ratio5.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.29 per share Price / Book11.28Profitability EPS (Most Recent Fiscal Year)($4.05) Net Income$-111,820,000.00 Net MarginsN/A Return on Equity-80.14% Return on Assets-67.82%Miscellaneous Employees117 Outstanding Shares32,130,000Market Cap$1.19 billion Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $37.10 -0.15 (-0.40 %) (As of 08/7/2020 11:38 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ODT News and Ratings via Email Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter. Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ODT shares have increased by 43.0% and is now trading at $37.07. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for Odonate Therapeutics. When is Odonate Therapeutics' next earnings date? Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Odonate Therapeutics. How were Odonate Therapeutics' earnings last quarter? Odonate Therapeutics Inc (NASDAQ:ODT) released its earnings results on Thursday, July, 30th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.98) by $0.11. View Odonate Therapeutics' earnings history. What price target have analysts set for ODT? 1 Wall Street analysts have issued twelve-month price targets for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' share price to reach $26.00 in the next twelve months. This suggests that the stock has a possible downside of 29.9%. View analysts' price targets for Odonate Therapeutics. Has Odonate Therapeutics been receiving favorable news coverage? Headlines about ODT stock have trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Odonate Therapeutics. Are investors shorting Odonate Therapeutics? Odonate Therapeutics saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 849,400 shares, an increase of 11.1% from the July 15th total of 764,300 shares. Based on an average daily trading volume, of 78,000 shares, the short-interest ratio is currently 10.9 days. Currently, 2.9% of the shares of the stock are short sold. View Odonate Therapeutics' Current Options Chain. Who are some of Odonate Therapeutics' key competitors? Some companies that are related to Odonate Therapeutics include Zai Lab (ZLAB), Schrodinger (SDGR), Legend Biotech (LEGN), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), HYPERA S A/S (HYPMY), Evotec (EVTCY), Blueprint Medicines (BPMC), FibroGen (FGEN), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT) and Opko Health (OPK). View all competitors. What other stocks do shareholders of Odonate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Bausch Health Companies (BHC), Five Prime Therapeutics (FPRX), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX) and Crispr Therapeutics (CRSP). Who are Odonate Therapeutics' key executives? Odonate Therapeutics' management team includes the following people: Mr. Kevin C. Tang, Chairman & CEO (Age 52)Mr. John G. Lemkey, Chief Operating Officer (Age 38)Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43) When did Odonate Therapeutics IPO? (ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager. What is Odonate Therapeutics' stock symbol? Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT." Who are Odonate Therapeutics' major shareholders? Odonate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.16%), Swiss National Bank (0.09%), Bessemer Group Inc. (0.06%), Strs Ohio (0.04%), Chartwell Investment Partners LLC (0.04%) and New York State Common Retirement Fund (0.04%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View institutional ownership trends for Odonate Therapeutics. Which major investors are selling Odonate Therapeutics stock? ODT stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, and UBS Group AG. View insider buying and selling activity for Odonate Therapeutics. Which major investors are buying Odonate Therapeutics stock? ODT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bessemer Group Inc., SG Americas Securities LLC, Russell Investments Group Ltd., New York State Common Retirement Fund, and Swiss National Bank. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang. View insider buying and selling activity for Odonate Therapeutics. How do I buy shares of Odonate Therapeutics? Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Odonate Therapeutics' stock price today? One share of ODT stock can currently be purchased for approximately $37.07. How big of a company is Odonate Therapeutics? Odonate Therapeutics has a market capitalization of $1.19 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe. What is Odonate Therapeutics' official website? The official website for Odonate Therapeutics is www.odonate.com. How can I contact Odonate Therapeutics? Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
